As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.

The following is a summary of "Prophylactic cranial irradiation improved the prognosis in pT1-2N0M0 small cell lung cancers ...

Bristol Myers Squibb said it is disappointed with the outcome of a study that examined whether one of its drugs could be used to treat a certain type of skin cancer. The drug, Opdualag, didn't meet ...

Using preoperative chest CT scans, researchers identified novel preoperative biomarkers for lung cancer recurrence ...

Strangers and friends have raised more than $150k for a man’s experimental life-saving cancer treatment after he found out ...

Blood clots form in response to signals from the lungs of cancer patients—not from other organ sites, as previously thought—according to a preclinical study by Weill Cornell Medicine, Memorial Sloan ...

Chapter 2 of Appraisal and funding of cancer drugs from July 2016 (including the new Cancer Drugs Fund) – A new deal for patients, taxpayers and industry states that for those drugs with a draft ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee D. Committee members are asked to declare any interests in the technology being ...

This guide will help you understand how NSCLC is treated, potential side effects, and how to navigate life beyond cancer.

NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced it ...

Lung cancer is a form of cancer wherein abnormal cells start to grow in the lungs in an uncontrolled way. According to World Cancer Research Fund, there were nearly 2.4 million new cases of lung ...

The researchers found that lobectomy was associated with improved survival compared with sublobar resection (hazard ratio for overall survival [OS] and lung-cancer specific survival [LCSS], 0.87 ...